According to the biopharmaceutical firm, CX-904 is the first T-cell-engaging bispecific antibody and the sixth therapeutic candidate from its Probody platform to enter clinical trial.
Shares rose 0.5% in premarket trading.
Price: 3.95, Change: +0.12, Percent Change: +3.13
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|
|--April Unemployment Rate Fell in 13 US States, Payr...|
|Marvell Technology Likely to See Fiscal Q1 Beat, Opp...|
|Research Alert: CFRA Keeps Buy Opinion On Shares Of ...|
|Terreno Realty Acquires Newark Industrial Property f...|